LENZ Therapeutics, Inc. (GRPH)
Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA.
Address
201 LOMAS SANTA FE DRIVE, SUITE 300
SOLANA BEACH, CA 92075
Founded
2017
Number of Employees
6
Website
http://www.graphitebio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | $42 | $55 | $66 | - | $54 |
| Average Price | - | - | - | - | - | - | - | $2.10 | $2.04 | $1.21 | - | $1.61 |
| # Shares Purchased | - | - | - | - | - | - | - | 19,799 | 27,059 | 54,355 | - | 33,738 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | 900.0% | 927.1% | 1,636.6% | - | 1,206.9% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | 31.7% | 37.3% | 31.3% | - | 33.4% |
| Excess Total Return | - | - | - | - | - | - | - | 868.3% | 889.8% | 1,605.2% | - | 1,173.5% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | 100% | 100% | 100% | - | 100% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at GRPH make a trade.
Creating a free account takes less than one minute